Lanzetta Marco, Petruzzo Palmina, Margreiter Raimund, Dubernard Jean Michel, Schuind Frederic, Breidenbach Warren, Lucchina Stefano, Schneeberger Stefan, van Holder Carlo, Granger Darla, Pei Guoxian, Zhao Jinmin, Zhang Xinying
Hand Surgery and Reconstructive Microsurgery. Milano-Bicocca University, Milano, Italy.
Transplantation. 2005 May 15;79(9):1210-4. doi: 10.1097/01.tp.0000157118.28394.fa.
Since May 2002 all groups performing hand transplantations have supplied detailed information to the International Registry on Hand and Composite Tissue Transplantation. This inaugural report provides a review of all hand transplants performed to date.
Between September 1998 and September 2004, 18 male patients underwent 24 hand/forearm/digit transplantations (11 monolateral and 4 bilateral hand transplantations, 2 bilateral forearm transplantations, and 1 thumb transplantation). The level of amputation was mostly at the distal forearm or wrist. The average age of the patient was 32 years. Time since hand loss ranged from 2 months to 22 years. Immunosuppressive therapy included tacrolimus, mycophenolate mofetil, rapamycin, and steroids; polyclonal or monoclonal antibodies were used for induction. Topical immunosuppression was administered in some patients. Follow-up period ranged from 17 to 70 months.
Patient survival was 100%. Graft survival was 100% at 1 and 2 years. Two cases of graft failure at a later date were caused by severe inflammation and progressive rejection in a noncompliant patient. Acute rejection episodes occurred in 12 patients within the first year. Rejection was reversible in all compliant patients. Side effects included opportunistic infections and metabolic complications. No life-threatening complications or malignancies were reported. All patients had achieved protective sensation, and 17 patients also achieved discriminative sensation. Extrinsic and intrinsic muscle recovery enabled patients to perform most daily activities.
Despite the enormous antigen load associated with composite tissue allograft, hand transplantation became a clinical reality with immunosuppression comparable to transplantation of solid organs.
自2002年5月起,所有进行手部移植的团队都向国际手部与复合组织移植登记处提供了详细信息。本首次报告对迄今为止进行的所有手部移植进行了综述。
1998年9月至2004年9月期间,18名男性患者接受了24次手/前臂/手指移植(11次单侧和4次双侧手部移植、2次双侧前臂移植以及1次拇指移植)。截肢水平大多位于前臂远端或腕部。患者的平均年龄为32岁。手部缺失时间从2个月至22年不等。免疫抑制治疗包括他克莫司、霉酚酸酯、雷帕霉素和类固醇;诱导治疗使用了多克隆或单克隆抗体。部分患者接受了局部免疫抑制治疗。随访期从17个月至70个月不等。
患者存活率为100%。1年和2年时移植物存活率均为100%。后期有2例移植物失败是由一名不依从患者的严重炎症和进行性排斥反应导致的。12名患者在第一年发生了急性排斥反应。所有依从患者的排斥反应均可逆转。副作用包括机会性感染和代谢并发症。未报告有危及生命的并发症或恶性肿瘤。所有患者均获得了保护性感觉,17名患者还获得了辨别性感觉。外在和内在肌肉的恢复使患者能够进行大多数日常活动。
尽管复合组织同种异体移植存在巨大的抗原负荷,但通过与实体器官移植相当的免疫抑制治疗,手部移植成为了临床现实。